# ASC40

Source: https://onco.cc/drugs/asc40/  
OnCo record `asc40` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ASC40 is an experimental small-molecule drug from Ascletis Pharmaceuticals in phase 3 trials for glioma & glioblastoma, with its target not yet stated publicly.

## Summary

ASC40 (TVB-2640) is a small-molecule drug developed by Ascletis Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ASC40 tablets administered orally once daily. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05118776 (Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM), in glioma & glioblastoma. The largest, NCT05118776, plans to enrol 136 participants (actual) with primary completion was scheduled for 2025-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: TVB-2640
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of ASC40: https://clinicaltrials.gov/search?intr=TVB-2640

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [Ascletis Pharma](https://onco.cc/companies/ascletis/)
- trials: [Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM](https://onco.cc/trials/nct05118776/)

---
JSON: https://onco.cc/api/v1/entities/asc40.json